An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
This report contains market size and forecasts of Hormone Refractory Breast Cancer in Global, including the following market information:
Global Hormone Refractory Breast Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hormone Refractory Breast Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tumor Markers Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hormone Refractory Breast Cancer include AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm and Boehringer Ingelheim GmbH, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hormone Refractory Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hormone Refractory Breast Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Breast Cancer Market Segment Percentages, by Type, 2021 (%)
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
Global Hormone Refractory Breast Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Breast Cancer Market Segment Percentages, by Application, 2021 (%)
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
Global Hormone Refractory Breast Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hormone Refractory Breast Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hormone Refractory Breast Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hormone Refractory Breast Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH